{"id":"NCT00533897","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase IIIB Subcutaneous Missed Dose Study","officialTitle":"A Phase IIIb, Multi-Center, Randomized, Withdrawal Study to Evaluate the Immunogenicity and Safety of Subcutaneous Administered Abatacept in Adults With Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-11","primaryCompletion":"2008-12","completion":"2014-02","firstPosted":"2007-09-24","resultsPosted":"2011-06-03","lastUpdate":"2015-04-23"},"enrollment":270,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Abatacept","otherNames":["Orencia","BMS-188667"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Abatacept","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to determine whether subcutaneous abatacept administered to patients with rheumatoid arthritis is associated with increased immunogenicity or increased safety events upon withdrawal and reintroduction.","primaryOutcome":{"measure":"Double-blind Withdrawal (DBW) Period; Percentage of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Antibody Responses by Enzyme-Linked Immunosorbent Assay (ELISA) at Day 169","timeFrame":"Day 169","effectByArm":[{"arm":"Abatacept in DBW Period","deltaMin":0,"sd":null},{"arm":"Placebo in DBW Period","deltaMin":1.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.119"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":27,"countries":["United States","Argentina","Canada","Mexico","South Africa"]},"refs":{"pmids":["21917824"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":10},"commonTop":["Upper respiratory tract infection","Bronchitis","Urinary tract infection","Sinusitis","Influenza"]}}